Osteo-P BGS
Commercial- Indications
- Bone regeneration, Orthopedic conditions
Company intelligence / Profile preview
Molecular Matrix has developed and commercialized Osteo-P®/Osteo-P™ Bone Graft Substitute, an FDA-cleared bone regeneration scaffold based on its proprietary hyper-crosslinked carbohydrate polymer platform. The product supports endogenous bone healing and offers advantages over traditional bone grafts by being synthetic, biocompatible, and rapidly replaced by new bone. Clinical results have enabled market entry in orthopedics since at least 2018.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Molecular Matrix.